Events

Retiro De Equipo (Recall) de Architect Active-B12 Reagent Kit. An in vitro diagnostic medical device (IVD)

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por Abbott Australasia Pty Ltd Diagnostic Division.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall
  • ID del evento
    RC-2016-RN-01579-1
  • Clase de Riesgo del Evento
    Class II
  • Fecha de inicio del evento
    2016-12-06
  • País del evento
    Australia
  • Fuente del evento
    DHTGA
  • URL de la fuente del evento
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2016-RN-01579-1
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    Abbott diagnostics has identified a lot specific stability issue with two reagent lots 10533up00 and 10534up00. as the reagent ages, relative light unit (rlu) values for the calibration curve will decrease causing patient results calculated from this depressed curve to over-recover, potentially resulting in falsely elevated patient results. controls may not reflect reagent instability as recalibration may result in control values within acceptable ranges.Abbott studies have determined the worst case magnitude of elevation to be up to 30% for active-b12 concentrations close to 20 pmol/l and up to 20% for concentrations close to 30 pmol/l.
  • Acción
    Abbott is advising users to discontinue use and immediately destroy any remaining inventory of the affected lots. The customer letter provided to users is to be reviewed with the Medical Director to determine if a review of results previously generated with the affected lots is required.

Device

Architect Active-B12 Reagent Kit. An in vitro diagnostic medical device (IVD)
  • Modelo / Serial
    Architect Active-B12 Reagent Kit. An in vitro diagnostic medical device (IVD).List Numbers: 3P24-25, 3P24-35Lot Numbers: 10533UP00, 15034UP00Expiry: 29 May 2017ARTG Number: 188927
  • Manufacturer
    Abbott Australasia Pty Ltd Diagnostic Division

Manufacturer

Abbott Australasia Pty Ltd Diagnostic Division
  • Empresa matriz del fabricante (2017)
    Abbott Laboratories
  • Comentario del fabricante
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DHTGA